- Home
- OMER vs SCPH Comparison
OMER vs SCPH Comparison
Compare OMER & SCPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OMER
- SCPH
- Stock Information
- Founded
- OMER 1994
- SCPH 2013
- Country
- OMER United States
- SCPH United States
- Employees
- OMER N/A
- SCPH N/A
- Industry
- OMER Biotechnology: Pharmaceutical Preparations
- SCPH Biotechnology: Pharmaceutical Preparations
- Sector
- OMER Health Care
- SCPH Health Care
- Exchange
- OMER Nasdaq
- SCPH Nasdaq
- Market Cap
- OMER 274.3M
- SCPH 299.0M
- IPO Year
- OMER 2009
- SCPH 2017
- Fundamental
- Price
- OMER $4.48
- SCPH $5.67
- Analyst Decision
- OMER Strong Buy
- SCPH Buy
- Analyst Count
- OMER 5
- SCPH 3
- Target Price
- OMER $18.00
- SCPH $12.00
- AVG Volume (30 Days)
- OMER 933.6K
- SCPH 2.0M
- Earning Date
- OMER 11-12-2025
- SCPH 11-12-2025
- Dividend Yield
- OMER N/A
- SCPH N/A
- EPS Growth
- OMER N/A
- SCPH N/A
- EPS
- OMER N/A
- SCPH N/A
- Revenue
- OMER N/A
- SCPH $49,969,000.00
- Revenue This Year
- OMER N/A
- SCPH $104.30
- Revenue Next Year
- OMER N/A
- SCPH $76.06
- P/E Ratio
- OMER N/A
- SCPH N/A
- Revenue Growth
- OMER N/A
- SCPH 107.79
- 52 Week Low
- OMER $2.95
- SCPH $1.94
- 52 Week High
- OMER $13.60
- SCPH $6.28
- Technical
- Relative Strength Index (RSI)
- OMER 56.41
- SCPH 64.40
- Support Level
- OMER $4.07
- SCPH $5.64
- Resistance Level
- OMER $4.72
- SCPH $5.65
- Average True Range (ATR)
- OMER 0.23
- SCPH 0.03
- MACD
- OMER 0.02
- SCPH -0.02
- Stochastic Oscillator
- OMER 61.19
- SCPH 66.67
About OMER Omeros Corporation
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.
About SCPH scPharmaceuticals Inc.
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs. The company's main product is Furoscix to treat congestion in patients with heart failure and edema in patients with chronic kidney disease. Furoscix is a novel formulation of furosemide contained in a pre-filled, Crystal Zenith cartridge and self-administered subcutaneously via a single-use, disposable, and wearable on-body delivery system.